197 related articles for article (PubMed ID: 33849970)
1. Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study.
ArdeshirRouhaniFard S; Dinh PC; Monahan PO; Fossa SD; Huddart R; Fung C; Song Y; Feldman DR; Hamilton RJ; Vaughn DJ; Martin NE; Kollmannsberger C; Einhorn L; Kroenke K; Travis LB
Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1129-1138. PubMed ID: 33849970
[TBL] [Abstract][Full Text] [Related]
2. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
Fung C; Sesso HD; Williams AM; Kerns SL; Monahan P; Abu Zaid M; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Kollmannsberger CK; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Lipshultz SE; Einhorn LH; Fossa SD; Travis LB;
J Clin Oncol; 2017 Apr; 35(11):1211-1222. PubMed ID: 28240972
[TBL] [Abstract][Full Text] [Related]
3. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL; Fung C; Monahan PO; Ardeshir-Rouhani-Fard S; Abu Zaid MI; Williams AM; Stump TE; Sesso HD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard C; Huddart RA; Kim J; Kollmannsberger C; Sahasrabudhe DM; Cook R; Fossa SD; Einhorn LH; Travis LB;
J Clin Oncol; 2018 May; 36(15):1505-1512. PubMed ID: 29617189
[TBL] [Abstract][Full Text] [Related]
4. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid M; Dinh PC; Monahan PO; Fung C; El-Charif O; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Sesso HD; Huddart R; Mushiroda T; Kubo M; Dolan ME; Einhorn LH; Fossa SD; Travis LB;
J Natl Compr Canc Netw; 2019 May; 17(5):459-468. PubMed ID: 31085753
[TBL] [Abstract][Full Text] [Related]
5. Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors.
Kerns SL; Fung C; Fossa SD; Dinh PC; Monahan P; Sesso HD; Frisina RD; Feldman DR; Hamilton RJ; Vaughn D; Martin N; Huddart R; Kollmannsberger C; Sahasrabudhe D; Ardeshir-Rouhani-Fard S; Einhorn L; Travis LB
JNCI Cancer Spectr; 2020 Aug; 4(4):pkaa022. PubMed ID: 32704617
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy.
Sanchez VA; Shuey MM; Dinh PC; Monahan PO; Fosså SD; Sesso HD; Dolan ME; Einhorn LH; Vaughn DJ; Martin NE; Feldman DR; Kroenke K; Fung C; Frisina RD; Travis LB
J Clin Oncol; 2023 Apr; 41(12):2211-2226. PubMed ID: 36626694
[TBL] [Abstract][Full Text] [Related]
7. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
[TBL] [Abstract][Full Text] [Related]
8. Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective.
Fosså SD; Haugnes HS; Dahl AA; Kiserud CE; Fosså A; Skalleberg J; Myklebust TÅ
Ann Oncol; 2023 Dec; 34(12):1165-1174. PubMed ID: 37739265
[TBL] [Abstract][Full Text] [Related]
9. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
10. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
[TBL] [Abstract][Full Text] [Related]
11. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.
Miaskowski C; Mastick J; Paul SM; Abrams G; Cheung S; Sabes JH; Kober KM; Schumacher M; Conley YP; Topp K; Smoot B; Mausisa G; Mazor M; Wallhagen M; Levine JD
J Cancer Surviv; 2018 Apr; 12(2):234-245. PubMed ID: 29159795
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.
Sanchez VA; Dinh PC; Rooker J; Monahan PO; Althouse SK; Fung C; Sesso HD; Einhorn LH; Dolan ME; Frisina RD; Travis LB
J Cancer Surviv; 2023 Feb; 17(1):27-39. PubMed ID: 36637632
[TBL] [Abstract][Full Text] [Related]
13. Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors.
Miaskowski C; Paul SM; Mastick J; Abrams G; Topp K; Smoot B; Kober KM; Chesney M; Mazor M; Mausisa G; Schumacher M; Conley YP; Sabes JH; Cheung S; Wallhagen M; Levine JD
J Pain Symptom Manage; 2018 Jul; 56(1):88-97. PubMed ID: 29524582
[TBL] [Abstract][Full Text] [Related]
14. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.
Ardeshirrouhanifard S; Fossa SD; Huddart R; Monahan PO; Fung C; Song Y; Dolan ME; Feldman DR; Hamilton RJ; Vaughn D; Martin NE; Kollmannsberger C; Dinh P; Einhorn L; Frisina RD; Travis LB
Ear Hear; 2022; 43(3):794-807. PubMed ID: 35067571
[TBL] [Abstract][Full Text] [Related]
15. Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy.
Miaskowski C; Paul SM; Mastick J; Schumacher M; Conley YP; Smoot B; Abrams G; Kober KM; Cheung S; Henderson-Sabes J; Chesney M; Mazor M; Wallhagen M; Levine JD
Eur J Oncol Nurs; 2018 Feb; 32():1-11. PubMed ID: 29353626
[TBL] [Abstract][Full Text] [Related]
16. Long-term sexual functioning in germ-cell tumor survivors.
Chovanec M; Vasilkova L; Petrikova L; Obertova J; Palacka P; Rejlekova K; Sycova-Mila Z; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M
BMC Cancer; 2020 Aug; 20(1):779. PubMed ID: 32819309
[TBL] [Abstract][Full Text] [Related]
17. Use of Medications for Treating Anxiety and Depression in Cancer Survivors in the United States.
Hawkins NA; Soman A; Buchanan Lunsford N; Leadbetter S; Rodriguez JL
J Clin Oncol; 2017 Jan; 35(1):78-85. PubMed ID: 28034075
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and predictors of depression and anxiety among survivors of myocardial infarction due to spontaneous coronary artery dissection.
Liang JJ; Tweet MS; Hayes SE; Gulati R; Hayes SN
J Cardiopulm Rehabil Prev; 2014; 34(2):138-42. PubMed ID: 24280906
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life, depression, and sexual function in testicular cancer survivors in a developing country: a Serbian experience.
Bumbasirevic U; Bojanic N; Pekmezovic T; Janjic A; Janicic A; Milojevic B; Tulic C
Support Care Cancer; 2013 Mar; 21(3):757-63. PubMed ID: 22933132
[TBL] [Abstract][Full Text] [Related]
20. Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy.
Stelwagen J; Lubberts S; Steggink LC; Steursma G; Kruyt LM; Donkerbroek JW; van Roon AM; van Gessel AI; van de Zande SC; Meijer C; Gräfin Zu Eulenburg CH; Oosting SF; Nuver J; Walenkamp AME; Jan de Jong I; Lefrandt JD; Gietema JA
Br J Cancer; 2020 Nov; 123(11):1599-1607. PubMed ID: 32921790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
